You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
华领医药(02552.HK)急弹16% 获瑞银重申「买入」评级
阿思达克 11-15 11:09

获瑞银重申「买入」华领医药(02552.HK)扭转连日寻底弱势,股价急弹16%报4.77元,成交130万股。

瑞银指,华领日前公布旗下糖尿病治疗的Dorzagliatin单药疗法III期临床研究(HMM0301)24周研究结果数据表现不俗,但股价却应声下跌,相信是由於流动性不足导致投资者离场。该行指,华领未来12个月将出现不少股价催化剂,包括市场非常关注明年次季公布的HMM0301 52周结果、首季公布HMM0302 24周结果、Dorzagliatin或於明年底递交上市申请,以及公司未来或与国际药企达成潜在合作,维持华领「买入」评级,以反映公司手持1.8亿美元现金流,估值约6亿美元属吸引,但目标价下调9.7%至12.1元,以反映考虑到产品商业化时间表延至明年底,预期Dorzagliatin要到2021年才可销售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account